Company Roche and Drug Keytruda will lead industry in 5 yrs

KoreaBIO announces projection on the pharmaceutical company and drug that will lead the industry in 2028

“Novo Nordisk and Lilly will enter Top 10 rank...sales of obesity drugs will rise”

“World’s top-selling drug at the end of this year will change from Humira to Keytruda”

A projection has been made that Roche will become the top global-grossing pharmaceutical company 5 years from now in 2028.

 

Evaluate, the global pharmaceutical market analysis institution that released such projections, also predicted that Keytruda would take over Humira’s throne and become the No.

 

1 grossing drug among pharmaceuticals.

 

On the 24th, KoreaBIO cited Evaluate’s data and predicted the top-grossing pharmaceutical companies and drugs for 2023.

 

According to KoreaBIo’s projections, biopharmaceutical companies that have been producing results will be in the top ranks this year.

 

The top-grossing company 5 years from now will be Roche, supported by the sales of its immuno-oncology drug ‘Tecentriq,’ multiple sclerosis treatment ‘Ocrevus’ and macular degeneration treatment disease drug ‘Vabysmo.’ No.2 and No.3 projections were the U.S.

 

companies Merck and AbbVie, respectively.

 

However, the difference in revenue between the top 3 companies is expected to be small.

 

No.

 

4 was expected to be Johnson & Johnson.

 

Top 10 Grossing ETC Pharmaceutical Companies in 2028

Pfizer, which ranked No.1 with unrivaled sales last year was thought to fall to 5th place.

 

In addition, Novartis, AstraZeneca, Sanofi, Novo Nordisk, and Eli Lilly were expected to make the top 10 sales list.

 

Compared to the current status, Novo Nordisk and Eli Lilly are new to the top 10 list in 2028, taking the place of BMS and GSK.

 

The expectation was that sales of diabetes and obesity drugs that the companies had recently released would surge, leading to a rise in the rankings.

 

The immuno-oncology drug Keytruda is expected to take over the top spot in terms of global sales.

 

In particular, it is predicted that Keytruda will rise to No.

 

1 this year, surpassing Humira, which had held the lead until now.

 

In addition to Keytruda, immuno-oncology drugs such as BMS's Opdivo, Roche’s Tecentriq, and AstraZeneca's Imfinzi are also expected to make the Top 10.

 

If the current upward trend continues, the total sales of immuno-oncology drugs are expected to surge from $40 billion in 2022 to $71 billion in 2028.

 

In addition, Sanofi’s atopic dermatitis treatment ‘Dupixent,’ Eli Lilly’s antidiabetic treatment ‘Mounjaro,’ Johnson & Johnson’s multiple myeloma treatment ‘Darzalex,’ AbbVie’s autoimmune disorder treatment ‘Skyrizi,’ Gilead Science’s HIV treatment ‘Biktarvy,’ Merck’s cervical cancer vaccine ‘Gardasil,’ and Vertex Pharmaceutical’s ‘Trikafta’ are also expected to make the Top 10 in 2028.

 

Top 10 Selling Drug Projections in 2028